X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6955) 6955
Publication (648) 648
Newsletter (132) 132
Book Review (36) 36
Book Chapter (28) 28
Book / eBook (18) 18
Government Document (16) 16
Conference Proceeding (12) 12
Magazine Article (9) 9
Newspaper Article (6) 6
Dissertation (5) 5
Paper (3) 3
Trade Publication Article (2) 2
Data Set (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (3537) 3537
humans (3361) 3361
index medicus (3154) 3154
male (2399) 2399
pyridines - pharmacology (2116) 2116
female (1761) 1761
pyridines - toxicity (1449) 1449
rats (1428) 1428
mice (1309) 1309
pyridines - therapeutic use (1232) 1232
oncology (1142) 1142
pyridines - administration & dosage (968) 968
pharmacology & pharmacy (949) 949
pyridine (945) 945
toxicity (890) 890
middle aged (886) 886
pyridines - adverse effects (820) 820
cancer (783) 783
aged (756) 756
adult (743) 743
dose-response relationship, drug (736) 736
toxicology (735) 735
pyridines - chemistry (673) 673
pyridines (603) 603
niacinamide - analogs & derivatives (579) 579
analysis (558) 558
biochemistry & molecular biology (548) 548
phenylurea compounds (545) 545
research (545) 545
antineoplastic agents - therapeutic use (512) 512
cell line, tumor (510) 510
treatment outcome (507) 507
apoptosis (462) 462
chemistry, medicinal (435) 435
pyridines - pharmacokinetics (430) 430
imidazoles - pharmacology (404) 404
structure-activity relationship (384) 384
rats, sprague-dawley (379) 379
antineoplastic agents - pharmacology (373) 373
article (362) 362
sorafenib (352) 352
care and treatment (350) 350
chemotherapy (347) 347
pyridines - metabolism (339) 339
neurosciences (334) 334
cells, cultured (330) 330
expression (330) 330
cell survival - drug effects (324) 324
antineoplastic combined chemotherapy protocols - therapeutic use (321) 321
apoptosis - drug effects (320) 320
time factors (319) 319
environmental sciences (309) 309
antineoplastic agents - adverse effects (308) 308
enzyme inhibitors - pharmacology (306) 306
protein kinase inhibitors - therapeutic use (304) 304
pyridines - chemical synthesis (304) 304
disease models, animal (303) 303
in-vitro (299) 299
health aspects (296) 296
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (293) 293
benzenesulfonates - therapeutic use (289) 289
proteins (284) 284
inhibition (279) 279
activation (278) 278
drug therapy (274) 274
chemistry, multidisciplinary (272) 272
cell biology (269) 269
cell line (269) 269
research article (269) 269
cell proliferation - drug effects (268) 268
administration, oral (265) 265
cytotoxicity (259) 259
cells (253) 253
multidisciplinary sciences (251) 251
therapy (251) 251
aged, 80 and over (249) 249
mice, inbred c57bl (249) 249
oxidative stress (249) 249
metabolism (246) 246
medicine (243) 243
molecular structure (241) 241
derivatives (240) 240
imidazoles - toxicity (233) 233
tumors (230) 230
benzenesulfonates - adverse effects (229) 229
protein kinase inhibitors - pharmacology (229) 229
rats, wistar (225) 225
chemistry (224) 224
drug administration schedule (221) 221
inhibitors (217) 217
phosphorylation (214) 214
signal transduction - drug effects (213) 213
drug combinations (212) 212
neoplasms - drug therapy (212) 212
liver (211) 211
alkaloids (210) 210
pharmacology (209) 209
drug interactions (206) 206
chemistry, organic (205) 205
antitumor-activity (204) 204
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6892) 6892
Japanese (91) 91
German (40) 40
Russian (39) 39
French (34) 34
Chinese (28) 28
Italian (15) 15
Spanish (9) 9
Polish (6) 6
Danish (4) 4
Serbian (4) 4
Czech (3) 3
Hungarian (3) 3
Ukrainian (2) 2
Bulgarian (1) 1
Dutch (1) 1
Portuguese (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Cancer, ISSN 0008-543X, 06/2017, Volume 123, Issue 12, pp. 2294 - 2302
In patients with doxorubicin‐pretreated nonadipocytic soft‐tissue sarcoma, regorafenib significantly improves quality‐adjusted survival in comparison with a... 
quality‐adjusted time without symptoms of progression or toxicity (Q‐TWiST) | quality‐adjusted survival | regorafenib | placebo | metastatic soft‐tissue sarcoma | quality-adjusted survival | quality-adjusted time without symptoms of progression or toxicity (Q-TWiST) | metastatic soft-tissue sarcoma | PAZOPANIB | ONCOLOGY | PALETTE | DOUBLE-BLIND | PHASE-3 TRIAL | SUNITINIB | RENAL-CELL CARCINOMA | Humans | Middle Aged | Fecal Incontinence - chemically induced | Male | Antineoplastic Agents - therapeutic use | Hand-Foot Syndrome - etiology | Diarrhea - chemically induced | Hypertension - chemically induced | Female | Pyridines - therapeutic use | Severity of Illness Index | Double-Blind Method | Liposarcoma - drug therapy | Proportional Hazards Models | Phenylurea Compounds - therapeutic use | Treatment Outcome | Hospitalization | Sarcoma - drug therapy | Mucositis - chemically induced | Asthenia - chemically induced | Sarcoma, Synovial - drug therapy | Quality of Life | Alopecia - chemically induced | Anorexia - chemically induced | Leiomyosarcoma - drug therapy | Aged | Cancer patients | Care and treatment | Dosage and administration | Sarcoma | Doxorubicin | Sensitivity analysis | Adjustment | Toxicity | Quality | Stability analysis | Patients | Survival | Cancer | Index Medicus | Abridged Index Medicus | Original
Journal Article
Journal Article
Journal Article
Toxicology and Applied Pharmacology, ISSN 0041-008X, 10/2013, Volume 272, Issue 1, pp. 245 - 255
Journal Article